ENZO BIOCHEM INC (ENZ) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:ENZ • US2941001024

0.3138 USD
-0.07 (-17.77%)
At close: Apr 17, 2025
0.32 USD
+0.01 (+1.98%)
After Hours: 4/17/2025, 8:15:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ENZ scores 2 out of 10 in our fundamental rating. ENZ was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of ENZ is average, but there are quite some concerns on its profitability. ENZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ENZ has reported negative net income.
  • In the past year ENZ has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ENZ reported negative net income in multiple years.
  • In the past 5 years ENZ reported 4 times negative operating cash flow.
ENZ Yearly Net Income VS EBIT VS OCF VS FCFENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • ENZ has a worse Return On Assets (-31.57%) than 86.67% of its industry peers.
  • The Return On Equity of ENZ (-45.72%) is worse than 71.43% of its industry peers.
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROIC N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ENZ Yearly ROA, ROE, ROICENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • ENZ has a Gross Margin of 44.74%. This is in the better half of the industry: ENZ outperforms 74.29% of its industry peers.
  • ENZ's Gross Margin has improved in the last couple of years.
  • ENZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
ENZ Yearly Profit, Operating, Gross MarginsENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ENZ has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ENZ has been increased compared to 5 years ago.
  • ENZ has a better debt/assets ratio than last year.
ENZ Yearly Shares OutstandingENZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENZ Yearly Total Debt VS Total AssetsENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ENZ has an Altman-Z score of -5.09. This is a bad value and indicates that ENZ is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ENZ (-5.09) is worse than 87.62% of its industry peers.
  • ENZ has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • ENZ has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. ENZ outperforms 84.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.09
ROIC/WACCN/A
WACC9.89%
ENZ Yearly LT Debt VS Equity VS FCFENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 3.04 indicates that ENZ has no problem at all paying its short term obligations.
  • ENZ has a better Current ratio (3.04) than 86.67% of its industry peers.
  • A Quick Ratio of 2.69 indicates that ENZ has no problem at all paying its short term obligations.
  • ENZ has a Quick ratio of 2.69. This is amongst the best in the industry. ENZ outperforms 81.90% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.69
ENZ Yearly Current Assets VS Current LiabilitesENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • ENZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -430.17%.
  • Looking at the last year, ENZ shows a very negative growth in Revenue. The Revenue has decreased by -54.20% in the last year.
  • The Revenue for ENZ have been decreasing by -17.04% on average. This is quite bad
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENZ Yearly Revenue VS EstimatesENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ENZ Yearly EPS VS EstimatesENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2022 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ENZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENZ Price Earnings VS Forward Price EarningsENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENZ Per share dataENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • ENZ has a Yearly Dividend Yield of 31.87%, which is a nice return.
  • In the last 3 months the price of ENZ has falen by -52.09%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.48, ENZ pays a better dividend. On top of this ENZ pays more dividend than 100.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.83, ENZ pays a better dividend.
Industry RankSector Rank
Dividend Yield 31.87%

5.2 History

  • ENZ does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ENZ Yearly Dividends per shareENZ Yearly Dividends per shareYearly Dividends per share 2024 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ENZ Yearly Income VS Free CF VS DividendENZ Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

More info and screens

Find the best dividend stocksShow peers with best dividend

ENZO BIOCHEM INC

NYSE:ENZ (4/17/2025, 8:15:28 PM)

After market: 0.32 +0.01 (+1.98%)

0.3138

-0.07 (-17.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-17
Earnings (Next)06-11
Inst Owners34.1%
Inst Owner Change-45.05%
Ins Owners10.57%
Ins Owner Change0%
Market Cap16.44M
Revenue(TTM)29.09M
Net Income(TTM)-21.31M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 31.87%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.56
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.74%
FCFM N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.14%
Cap/Sales 2.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.69
Altman-Z -5.09
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)89.52%
Cap/Depr(5y)102.77%
Cap/Sales(3y)7.08%
Cap/Sales(5y)5.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.68%
OCF growth 3YN/A
OCF growth 5YN/A

ENZO BIOCHEM INC / ENZ FAQ

What is the ChartMill fundamental rating of ENZO BIOCHEM INC (ENZ) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENZ.


What is the valuation status for ENZ stock?

ChartMill assigns a valuation rating of 0 / 10 to ENZO BIOCHEM INC (ENZ). This can be considered as Overvalued.


What is the profitability of ENZ stock?

ENZO BIOCHEM INC (ENZ) has a profitability rating of 1 / 10.


What is the financial health of ENZO BIOCHEM INC (ENZ) stock?

The financial health rating of ENZO BIOCHEM INC (ENZ) is 5 / 10.